Browse by Audience
Skip to content
Papers of the Week
Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being and Pain Catastrophizing.
Abstract
Previous studies demonstrate decreased pain scores with ziconotide as a first-line agent for intrathecal drug therapy(IDT). Subset analysis suggests that patients with neuropathic pain have greater improvement. Here we prospectively examine the role of first-line ziconotide IDT on the tridimensional pain experience in ziconotide IDT naïve patients with neuropathic pain.